反応式
[F:1][C:2]1[CH:3]=[C:4]([C@H:8]2[CH2:12][CH2:11][CH2:10][N:9]2[C:13]2[CH:18]=[CH:17][N:16]3[N:19]=[CH:20][C:21]([NH2:22])=[C:15]3[N:14]=2)[CH:5]=[CH:6][CH:7]=1.C1N=CN([C:28]([N:30]2[CH:34]=N[CH:32]=[CH:31]2)=[O:29])C=1.N1CC[O:38][CH2:37]C1>C(Cl)Cl>[F:1][C:2]1[CH:3]=[C:4]([C@H:8]2[CH2:12][CH2:11][CH2:10][N:9]2[C:13]2[CH:18]=[CH:17][N:16]3[N:19]=[CH:20][C:21]([NH:22][C:28]([N:30]4[CH2:31][CH2:32][O:38][CH2:37][CH2:34]4)=[O:29])=[C:15]3[N:14]=2)[CH:5]=[CH:6][CH:7]=1参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
To a DCM (0.8 mL) solution of (R)-5-(2-(3-fluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-amine (50 mg, 0.17 mmol) was added CDI (41 mg, 0.25 mmol) at ambient temperature in one portion. After stirring two hours, morpholine (22 mg, 0.25 mmol) was added in one portion. The reaction was stirred for 5 minutes before it was concentrated and directly purified by reverse-phase column chromatography, eluting with 5 to 54% acetonitrile/water to yield the final product as a yellowish foamy powder (69 mg, 100% yield). MS (apci) m/z=411.2 (M+H).
後処理
- stirringThe reaction was stirred for 5 minutes before it
- concentrationwas concentrated
- customdirectly purified by reverse-phase column chromatography
- washeluting with 5 to 54% acetonitrile/water
出典と根拠
- ORDレコード
- ord-c82f437782b84f2b94be26357ede6e07
- 出典データセット
- uspto-grants-2016_09
- 特許番号
- US09447104B2
関連ノート
読み込み中…